ArticleEuropean journal of nuclear medicine and molecular imaging2026
Systematic evaluation of response and adverse events in mCRPC patients treated with different combinations of [
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose
methodsA total of 19 consecutive patients treated with ALCT on compassionate use basis at our department were evaluated. Patients were divided into two different subgroups, depending on the
resultsAccording to the RECIP composite classification, 4 of 10 (40%) of patients from Gr1 and 5 of 9 (56%) from Gr2 showed a partial response, while 4/10 (40%) and 2/9 (22%) of patients from Gr1 and 2, respectively, showed progressive disease. After 2 cycles of ALCT the following adverse events newly developed or worsened by at least one grade: anemia in 2/10 (20%) patients from Gr1 and 3/9 (33%) patients from Gr2; thrombocytopenia in 1/10 (10%) patients from Gr1; leukopenia in 4/10 (40%) from Gr1 and 2/9 (22%) from Gr2; weight loss in 1/10 (10%) from Gr1 and 2/9 (22%) from Gr2 and xerostomia in 3/10 (30%) from Gr1 and 5/9 (56%) from Gr2. There was no significant difference between the two groups in respect to absolute values after therapy or pre- and post-therapy difference in any of the laboratory or imaging parameters evaluated.
conclusionAlthough no significant difference in response or adverse events could be found between the two treatment groups, ALCT with higher
Indexed as
Identifiers
41530551What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.